Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab
Integrating BR classification with BCLC staging identified BCLC-C/BR1 patients as optimal candidates for conversion therapy after ATZ/BEV treatment. These findings support incorporating anatomical and oncological criteria into systemic strategies to enable curative interventions in advanced HCC.
Authors
- Miwa Kawanaka (ORCID: https://orcid.org/0000-0003-2341-5199)
- Akinobu Takaki
- Nozomi Miyake
- Kenji Kuwaki (ORCID: https://orcid.org/0000-0002-3908-1288)
- Shota Iwado
- Tetsuya Yasunaka
- TOSHIFUMI TADA
- Junichi Toshimori
- Emi Tanaka (ORCID: https://orcid.org/0000-0002-0456-2882)
- Hideki Onishi (ORCID: https://orcid.org/0000-0002-7283-3517)
- Takuya Adachi (ORCID: https://orcid.org/0000-0003-1593-6621)
- Yasuto Takeuchi
- Hiroaki Hagihara
- Hiroyuki Takabatake
- Masahiko Sue
- Kazuya Kariyama
- Kazuhiro Nouso
- Motoyuki Otsuka
- Shinichiro Nakamura
- Masahiro Sakata
Institutions
- Fukuyama University (JP)
- Kurashiki Central Hospital (JP)
- Mito Saiseikai General Hospital (JP)
- Okayama University Hospital (JP)
- Fukuyama City Hospital (JP)
- Okayama Red Cross General Hospital (JP)
- Himeji Red Cross Hospital (JP)
- Okayama Saiseikai General Hospital (JP)
- Sumitomo Besshi Hospital (JP)
- Kobe University (JP)
Publication Details
- Journal
- Hepatology Research
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1111/hepr.70138
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development